Document is current
Any future updates will be listed below
-
Authors
Okabe, Seiichi
Gotoh, Akihiko
-
Funding
Funding for this research was provided by:
Seiichi Okabe (20K07644)
- License Information
-
More Information
Article History
Received: 4 February 2023
Accepted: 16 August 2023
First Online: 5 September 2023
Declarations
:
: Not applicable.
: Not applicable.
: A.G. reports research funding from Eisai Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Taiho Pharmaceutical Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; Nippon Shinyaku Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; MSD K.K.; Otsuka Pharmaceutical Co., Ltd.; Sumitomo Pharma Co., Ltd.; Nippon Shinyaku Co., Ltd.; Bayer Yakuhin, Ltd.; Daiichi Sankyo Co., Ltd.; and Nihon Pharmaceutical Co., Ltd. A.G. reports honoraria from Novartis Pharma K.K.; Alexion Pharmaceuticals, Inc.; Eisai Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Taiho Pharmaceutical Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; Nippon Shinyaku Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; Otsuka Pharmaceutical Co., Ltd.; Sumitomo Pharma Co., Ltd.; Daiichi Sankyo Co., Ltd.; Nihon Pharmaceutical Co., Ltd.; Kyowa Kirin Co., Ltd.; Janssen Pharmaceutical K.K.; Pfizer Japan Inc.; and Sanofi K.K. A.G. reports consulting fees from PharmaEssentia Japan K.K.; Chugai Pharmaceutical Co., Ltd.; and Alexion Pharmaceuticals, Inc. In addition, A.G. reports participation on a data safety monitoring board or advisory board of PharmaEssentia Japan K.K.; Chugai Pharmaceutical Co., Ltd.; and Alexion Pharmaceuticals, Inc. S.O. reports no conflicts of interest.
